CELL EVALUATION & THERAPY

霍林斯癌症中心(肝癌)细胞评估和治疗(CET)共享资源为肝癌提供 调查人员全面分析流式细胞仪和高速细胞分选服务，并具备 生产用于转译研究的人类细胞和组织产品。世界银行的使命是 CET共享资源是提供一个综合平台，在这个平台上，肝细胞癌用户可以评估临床前或 临床实验数据以特定于细胞的方式，并使用细胞制造设施将细胞 将产品提供给患者。导演：Kevin F.Staveley-O‘Carroll，医学博士，两位副导演， Amanda C.LaRue博士和Shikhar Mehrotra博士，该机构提供广泛的专业知识， 教育平台，并在该设施内开发新的方法。 CC CET共享资源的具体目标是提供： ·多参数和多激光测量，包括细胞凋亡、细胞增殖、细胞周期 分布、免疫表型以及细胞内蛋白、膜的检测 微扰和生物活性分子。 ·扩展细胞疗法和基于基因疗法的生物治疗产品，适用于I期和II期临床 联邦法规要求采用现行cGMP的研究。 ·免疫监测服务，以评估患者的免疫反应，并为基本的 实验室实验。 ·在准备基于细胞和可能的基因疗法的INDS方面的监管专门知识。 ·基于细胞表面标记免疫染色和/或侧群染色的高速细胞分选。 ·在实验设计、样品制备和数据分析方面提供咨询和协助。 ·关于使用常规流式细胞仪技术和分析设备的培训。 ·新的和/或特定于肝细胞癌研究人员的新型流式细胞仪分析方面的高级培训 申请。 ·采用新方法，协助协作组成员开展前沿研究。 在当前CCSG项目期内，由CET支持的实验已取得18项以上的成功 NCI资助的研究项目赠款和100多份同行评议的出版物。

The Hollings Cancer Center (HCC) Cell Evaluation & Therapy (CET) Shared Resource offers HCC investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to generate human cellular and tissue-based products for use in translational research. The mission of the CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors, Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active educational platform, and development of new methodologies within the facility. The specific objectives of the HCC CET Shared Resource are to provide: • Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane perturbations, and bioactive molecules. • Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical studies employing current cGMP as required by federal regulations. • Immune monitoring services to evaluate the immune response in patients and provide data for basic laboratory experiments. • Regulatory expertise in the preparation of cell and possibly gene therapy based INDs. • High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining. • Consultation and assistance concerning experimental design, sample preparation, and data analysis. • Training in the use of routine flow cytometric technology and analytical equipment. • Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers' applications. • New methods to assist HCC members in performing cutting-edge research. CET-supported experiments during the current CCSG project period have led to the success of more than 18 NCI-funded research project grants and more than 100 peer-reviewed publications.